Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29813255 | 0.88 | GABRG2 (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL16212535 | 0.84 | GABRG2 (0.35) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6110315 | 0.79 | GABRG2 (0.38) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6097927 | 0.74 | MAP4K4 (0.36) | SCN4ASCN9AMKNK1MKNK2 | |
| SCHEMBL30807496 | 0.73 | SCN4A (0.30) | SCN4ASCN9A | |
| SCHEMBL18770368 | 0.71 | GABRG2 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9838862 | 0.69 | KDR (0.33) | SCN4ASCN9A | |
| SCHEMBL18986536 | 0.67 | MAP4K4 (0.39) | SCN4ASCN9AMKNK1MKNK2 | |
| SCHEMBL14661735 | 0.63 | PARP1 (0.41) | — | |
| SCHEMBL7519926 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081082-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| EP-3930759-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2022-01-05 | — | — | EP | claimed |
| US-20260083752-A1 | PHARMACEUTICAL METHODS, COMPOSITIONS AND COMBINATIONS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-03-26 | — | — | US | disclosed |
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-3224258-A1 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | Genentech, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016086200-A9 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016086200-A1 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2615916-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | SCN4A 4080/4885SCN9A 4503/4885GABRA1 2749/4885 |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | SCN4A 3783/4885SCN9A 3778/4885GABRA1 2783/4885 |
| US-20260083752-A1 | PHARMACEUTICAL METHODS, COMPOSITIONS AND COMBINATIONS | EP300, CREBBP, BMI1 | SCN4A 1233/4885SCN9A 2422/4885GABRA1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.